| Shareholder | |||||
|---|---|---|---|---|---|
Eli Lilly Investment Consulting (Shanghai) Co., Ltd. | 16.53% | 70.54M | 0.02% | +0 | |
Xueming QianExecutive Chairman & CEO | 12.22% | 52.15M | <0.01% | +30.00K | |
Chengtong Fund Management Co., Ltd. | 6.67% | 28.47M | <0.01% | +0 | |
Temasek Holdings (Private) Limited | 6.58% | 28.09M | <0.01% | +0 | |
China Merchants Kunlun Capital Co., Ltd. | 2.57% | 10.95M | <0.01% | +0 | |
Li XuHead of CDx, Member of Scientific Advisory Board, Strategic Advisor to CEO & Non-Executive Director | 0.32% | 1.35M | <0.01% | +10.00K | |
Dimensional Fund Advisors LP | 0.16% | 665.50K | 0.07% | -304.06K | |
Zhihua ZhangFormer Independent Non-Executive Director | <0.01% | 40.00K | <0.01% | +10.00K | |
Jiasong TangIndependent Non-Executive Director | <0.01% | 40.00K | <0.01% | +10.00K | |
Kumar SrinivasanIndependent Non-Executive Director | <0.01% | 30.00K | <0.01% | +10.00K | |
Wei ChenIndependent Non-Executive Director | <0.01% | 20.00K | 0.00% | +0 |
